May Wenche Jøraholmen

Dr. May Wenche Jøraholmen

UiT The Arctic University of Norway
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
May Wenche JøraholmenMay Wenche Jøraholmen
May Wenche Jøraholmen
Natasa Skalko-BasnetNatasa Skalko-Basnet
Natasa Skalko-Basnet
GAGanesh Acharya
Ganesh Acharya
Purusotam BasnetPurusotam Basnet
Purusotam Basnet

1 September 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
May Wenche JøraholmenMay Wenche Jøraholmen
May Wenche Jøraholmen
Željka VanićŽeljka Vanić
Željka Vanić
Ingunn ThoIngunn Tho
Ingunn Tho
Natasa Skalko-BasnetNatasa Skalko-Basnet
Natasa Skalko-Basnet

1 April 2017 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
May Wenche JøraholmenMay Wenche Jøraholmen
May Wenche Jøraholmen
Purusotam BasnetPurusotam Basnet
Purusotam Basnet
GAGanesh Acharya
Ganesh Acharya
Natasa Skalko-BasnetNatasa Skalko-Basnet
Natasa Skalko-Basnet

27 January 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
May Wenche JøraholmenMay Wenche Jøraholmen
May Wenche Jøraholmen
Purusotam BasnetPurusotam Basnet
Purusotam Basnet
MTMia Jonine Tostrup
Mia Jonine Tostrup
SMSabrin Moueffaq
Sabrin Moueffaq
Natasa Skalko-BasnetNatasa Skalko-Basnet
Natasa Skalko-Basnet
Natural polyphenols, such as resveratrol (RES) or epicatechin (EPI), are attractive for treatments of various diseases, including vaginal infections and inflammation, because of their strong anti-oxidative and anti-inflammatory properties. However, their low solubility and consequent poor bioavailability limit their therapeutic uses. To overcome these limitations, a vaginal delivery system comprising either RES or EPI liposomes-in-hydrogel was developed. This system permits therapeutic action of both liposomal polyphenol (RES or EPI) and chitosan-based hydrogel. Liposomes of around 200 nm and entrapment efficiency of 81% and 77% for RES and EPI, respectively, were incorporated into chitosan hydrogel, respectively. Medium molecular weight chitosan (2.5%, w/w) was found to have optimal texture properties and mucoadhesiveness in ex vivo conditions. The in vitro release studies confirmed the sustained release of polyphenols from the system. Both liposomal polyphenols and polyphenols-in-liposomes-in-hydrogel exhibited only minor effects on cell toxicity. EPI showed superior radical scavenging activity at lower concentrations compared to antioxidants vitamin C and E. Anti-inflammatory activity expressed as the inhibitory activity of formulations on the NO production in the LPS-induced macrophages (RAW 264.7) confirmed the superiority of EPI liposomes-in-hydrogel. The plain liposomes-in-hydrogel also exhibited potent anti-inflammatory activity, suggesting that chitosan hydrogel acts in synergy regarding anti-inflammatory effect of formulation.

8 December 2021 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Lisa Myrseth HemmingsenLisa Myrseth Hemmingsen
Lisa Myrseth Hemmingsen
Natasa Skalko-BasnetNatasa Skalko-Basnet
Natasa Skalko-Basnet
May Wenche JøraholmenMay Wenche Jøraholmen
May Wenche Jøraholmen
Chitosan is one of the most studied natural origin polymers for biomedical applications. This review focuses on the potential of chitosan in localized antimicrobial therapy to address the challenges of current rising antimicrobial resistance. Due to its mucoadhesiveness, chitosan offers the opportunity to prolong the formulation residence time at mucosal sites; its wound healing properties open possibilities to utilize chitosan as wound dressings with multitargeted activities and more. We provide an unbiased overview of the state-of-the-art chitosan-based delivery systems categorized by the administration site, addressing the site-related challenges and evaluating the representative formulations. Specifically, we offer an in-depth analysis of the current challenges of the chitosan-based novel delivery systems for skin and vaginal infections, including its formulations optimizations and limitations. A brief overview of chitosan’s potential in treating ocular, buccal and dental, and nasal infections is included. We close the review with remarks on toxicity issues and remaining challenges and perspectives.

31 January 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
May Wenche JøraholmenMay Wenche Jøraholmen
May Wenche Jøraholmen
ABAbhilasha Bhargava
Abhilasha Bhargava
KJKjersti Julin
Kjersti Julin
MJMona Johannessen
Mona Johannessen
Natasa Skalko-BasnetNatasa Skalko-Basnet
Natasa Skalko-Basnet
Topical administration of drugs into the vagina can provide local therapy of vaginal infections, preventing the possible systemic side effects of the drugs. The natural polysaccharide chitosan is known for its excellent mucoadhesive properties, safety profile, and antibacterial effects, and thus it can be utilized in improving localized vaginal therapy by prolonging the residence time of a drug at the vaginal site while acting as an antimicrobial in synergy. Therefore, we aimed to explore the potential of chitosan, namely chitosan-coated liposomes and chitosan hydrogel, as an excipient with intrinsic antimicrobial properties. Liposomes were prepared by the thin-film hydration method followed by vesicle size reduction by sonication to the desired size, approximately 200 nm, and coated with chitosan (0.01, 0.03, 0.1, and 0.3%, w/v, respectively). The mucoadhesive properties of chitosan-coated liposomes were determined through their binding efficiency to mucin compared to non-coated liposomes. Non-coated liposomal suspensions were incorporated in chitosan hydrogels forming the liposomes-in-hydrogel formulations, which were further assessed for their texture properties in the presence of biological fluid simulants. The antibacterial effect of chitosan-coated liposomes (0.03%, 0.1% and 0.3%, w/v) and chitosan hydrogels (0.1% and 0.3%, w/w) on Staphylococcus epidermidis and Staphylococcus aureus was successfully confirmed.